TY - JOUR
T1 - Convulxin binding to platelet receptor GPVI
T2 - Competition with collagen related peptides
AU - Niedergang, F.
AU - Alcover, A.
AU - Knight, C. G.
AU - Farndale, R. W.
AU - Barnes, M. J.
AU - Francischetti, I. M.B.
AU - Bon, C.
AU - Leduc, M.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2000/6/24
Y1 - 2000/6/24
N2 - Convulxin (CVX), a potent platelet aggregating protein from the venom of the snake Crotalus durissus terrificus, is known to bind to the platelet collagen receptor, glycoprotein VI (GPVI). CVX binding to human platelets was investigated by flow cytometry, using fluorescein labeled convulxin (FITC-CVX). Scatchard analysis indicated high and low affinity binding sites with Kd values of 0.6 and 4 nM and Bmax values of 1200 and 2000 binding sites per platelet. FITC-CVX binding was inhibited by collagen related peptides (CRPs) comprising a repeated GPO sequence, namely GCO(GPO)10GCOGNH2 and GKO(GPO)10GKOGNH2, which also bind to receptor GPVI. These peptides (monomeric or cross-linked forms) gave a high affinity inhibition of 10-20% for concentrations between 10 ng/ml and 5 μg/ml, followed by a second phase of inhibition at concentrations greater than 5 μg/ml. It was shown also that the inhibition of FITC-CVX binding by CRPs was independent on the time of preincubation of platelets with CRPs, and the same percentage of inhibition was seen with various concentrations of convulxin. Confocal microscopy of the distribution of FITC-CVX binding sites on platelets showed an homogeneous distribution of FITC-CVX bound to GPVI, although some limited clustering may exist. (C) 2000 Academic Press.
AB - Convulxin (CVX), a potent platelet aggregating protein from the venom of the snake Crotalus durissus terrificus, is known to bind to the platelet collagen receptor, glycoprotein VI (GPVI). CVX binding to human platelets was investigated by flow cytometry, using fluorescein labeled convulxin (FITC-CVX). Scatchard analysis indicated high and low affinity binding sites with Kd values of 0.6 and 4 nM and Bmax values of 1200 and 2000 binding sites per platelet. FITC-CVX binding was inhibited by collagen related peptides (CRPs) comprising a repeated GPO sequence, namely GCO(GPO)10GCOGNH2 and GKO(GPO)10GKOGNH2, which also bind to receptor GPVI. These peptides (monomeric or cross-linked forms) gave a high affinity inhibition of 10-20% for concentrations between 10 ng/ml and 5 μg/ml, followed by a second phase of inhibition at concentrations greater than 5 μg/ml. It was shown also that the inhibition of FITC-CVX binding by CRPs was independent on the time of preincubation of platelets with CRPs, and the same percentage of inhibition was seen with various concentrations of convulxin. Confocal microscopy of the distribution of FITC-CVX binding sites on platelets showed an homogeneous distribution of FITC-CVX bound to GPVI, although some limited clustering may exist. (C) 2000 Academic Press.
UR - http://www.scopus.com/inward/record.url?scp=0034709642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034709642&partnerID=8YFLogxK
U2 - 10.1006/bbrc.2000.2940
DO - 10.1006/bbrc.2000.2940
M3 - Article
C2 - 10873594
AN - SCOPUS:0034709642
SN - 0006-291X
VL - 273
SP - 246
EP - 250
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 1
ER -